Joern Aldag

Joern Aldag leads the Hookipa team as Chief Executive Officer (CEO). Prior to joining Hookipa in June 2016, Joern was CEO of NASDAQ-listed uniQure N.V., a company pioneering adeno-associated virus-based gene therapy. Under his leadership from 2009-2015, uniQure received the first-ever approval of a gene therapy product from the European Medicines Agency (EMA). He also helped to build uniQure’s pipeline of gene therapy products across several disease areas, raised approximately $200M through a NASDAQ-listing and follow-on fundraising, and closed a multibillion-dollar collaboration in cardiovascular gene therapy. From 1997 to 2008, Joern was President and CEO of Evotec AG. He co-founded G7 Therapeutics in 2013, a company focused on developing G protein-coupled receptors, which was successfully sold to Heptares in 2016. From 2007 to 2018 Joern was Chairman of SIX-listed Molecular Partners, Zurich Switzerland. He is a Non-Executive Director at Unum Therapeutics, and holds Business degrees from the European Business School and Harvard Business School (AMP).